Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery

Antiviral Research

Volumn 94, Issue 3, 2012, Pages 195-207

  Kneidinger, Doris ^a   IbriŠimović, Mirza ^a   Lion, Thomas ^a   Klein, Reinhard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adenovirus; Infection; RNA interference; SiRNA

Indexed keywords

DNA POLYMERASE; E1A PROTEIN; POL PROTEIN; PROTEINASE; SMALL INTERFERING RNA;

ADENOVIRUS; ARTICLE; CELL DEATH; CELL VIABILITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA REPLICATION; DNA SYNTHESIS; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGENY; RNA INTERFERENCE; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; ANTIVIRAL AGENTS; BIOLOGICAL AGENTS; DNA, VIRAL; GENE SILENCING; HUMANS; RNA, SMALL INTERFERING; VIRAL PROTEINS; VIRUS REPLICATION;

ADENOVIRIDAE; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 5; MIRIDAE;

EID: 84859931726     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.03.011     Document Type: Article

References (65)

1. Andersson M.G., Haasnoot P.C., Xu N., Berenjian S., Berkhout B., Akusjarvi G. Suppression of RNA interference by adenovirus virus-associated RNA. J. Virol. 2005, 79:9556-9565.
2. Arbuthnot P. Harnessing RNA interference for the treatment of viral infections. Drug News Perspect. 2010, 23:341-350.
3. Berk A.J. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 2005, 24:7673-7685.
4. Blackford A.N., Grand R.J. Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation. J. Virol. 2009, 83:4000-4012.
5. Blanke C., Clark C., Broun E.R., Tricot G., Cunningham I., Cornetta K., Hedderman A., Hromas R. Evolving pathogens in allogeneic bone marrow transplantation: increased fatal adenoviral infections. Am. J. Med. 1995, 99:326-328.
6. Carthew R.W., Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 2009, 136:642-655.
7. Castanotto D., Sakurai K., Lingeman R., Li H., Shively L., Aagaard L., Soifer H., Gatignol A., Riggs A., Rossi J.J. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucl. Acids Res. 2007, 35:5154-5164.
8. Chakrabarti S., Mautner V., Osman H., Collingham K.E., Fegan C.D., Klapper P.E., Moss P.A., Milligan D.W. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002, 100:1619-1627.
9. Chen Z., Xu Z.F., Ye J.J., Yao H.P., Zheng S., Ding J.Y. Combination of small interfering RNAs mediates greater inhibition of human hepatitis B virus replication and antigen expression. J. Zhejiang Univ. Sci. B 2005, 6:236-241.
10. Chung Y.S., Kim M.K., Lee W.J., Kang C. Silencing E1A mRNA by RNA interference inhibits adenovirus replication. Arch. Virol. 2007, 152:1305-1314.
11. Cuconati A., Degenhardt K., Sundararajan R., Anschel A., White E. Bak and Bax function to limit adenovirus replication through apoptosis induction. J. Virol. 2002, 76:4547-4558.
12. Davidson B.L., McCray P.B. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 2011, 12:329-340.
13. de Jong R.N., van der Vliet P.C., Brenkman A.B. Adenovirus DNA replication: protein priming, jumping back and the role of the DNA binding protein DBP. Curr. Top. Microbiol. Immunol. 2003, 272:187-211.
14. Ebner K., Rauch M., Preuner S., Lion T. Typing of human adenoviruses in specimens from immunosuppressed patients by PCR-fragment length analysis and real-time quantitative PCR. J. Clin. Microbiol. 2006, 44:2808-2815.
15. Echavarria M. Adenoviruses in immunocompromised hosts. Clin. Microbiol. Rev. 2008, 21:704-715.
16. Eckstein A., Grossl T., Geisler A., Wang X., Pinkert S., Pozzuto T., Schwer C., Kurreck J., Weger S., Vetter R., Poller W., Fechner H. Inhibition of adenovirus infections by siRNA-mediated silencing of early and late adenoviral gene functions. Antiviral. Res. 2010, 88:86-94.
17. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
18. Fechner H., Wang X., Srour M., Siemetzki U., Seltmann H., Sutter A.P., Scherubl H., Zouboulis C.C., Schwaab R., Hillen W., Schultheiss H.P., Poller W. A novel tetracycline-controlled transactivator-transrepressor system enables external control of oncolytic adenovirus replication. Gene Ther. 2003, 10:1680-1690.
19. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
20. Flint S.J. Regulation of adenovirus mRNA formation. Adv. Virus Res. 1986, 31:169-228.
21. Flint S.J., Gonzalez R.A. Regulation of mRNA production by the adenoviral E1B 55-kDa and E4 Orf6 proteins. Curr. Top. Microbiol. Immunol. 2003, 272:287-330.
22. Formstecher E., Reverdy C., Cholay M., Planquette C., Trouplin V., Lehrmann H., Aresta S., Calabrese A., Arar K., Daviet L., Colland F. Combination of active and inactive siRNA targeting the mitotic kinesin Eg5 impairs silencing efficiency in several cancer cell lines. Oligonucleotides 2006, 16:387-394.
23. Ghildiyal M., Zamore P.D. Small silencing RNAs: an expanding universe. Nat. Rev. Genet. 2009, 10:94-108.
24. Gordon Y.J., Aoki K., Kinchington P.R. Adenovirus keratoconjunctivitis. Ocular Infection and Immunity 1996, 877-894. Mosby, St. Louis. J.S. Pepose, G.N. Holland, K.R. Wilhelmus (Eds.).
25. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977, 36:59-74.
26. Greber U.F., Webster P., Weber J., Helenius A. The role of the adenovirus protease on virus entry into cells. EMBO J. 1996, 15:1766-1777.
27. Haasnoot J., Westerhout E.M., Berkhout B. RNA interference against viruses: strike and counterstrike. Nat. Biotechnol. 2007, 25:1435-1443.
28. Hale G.A., Heslop H.E., Krance R.A., Brenner M.A., Jayawardene D., Srivastava D.K., Patrick C.C. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transpl. 1999, 23:277-282.
29. Hartline C.B., Gustin K.M., Wan W.B., Ciesla S.L., Beadle J.R., Hostetler K.Y., Kern E.R. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J. Infect. Dis. 2005, 191:396-399.
30. Heemskerk B., Lankester A.C., van Vreeswijk T., Beersma M.F., Claas E.C., Veltrop-Duits L.A., Kroes A.C., Vossen J.M., Schilham M.W., van Tol M.J. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J. Infect. Dis. 2005, 191:520-530.
31. Hitt M.M., Graham F.L. Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication. Virology 1990, 179:667-678.
32. Howard D.S., Phillips I.G., Reece D.E., Munn R.K., Henslee-Downey J., Pittard M., Barker M., Pomeroy C. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 1999, 29:1494-1501.
33. Huntzinger E., Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat. Rev. Genet. 2011, 12:99-110.
34. Hutvagner G., Simard M.J. Argonaute proteins: key players in RNA silencing. Nat. Rev. Mol. Cell. Biol. 2008, 9:22-32.
35. Iftode C., Flint S.J. Viral DNA synthesis-dependent titration of a cellular repressor activates transcription of the human adenovirus type 2 IVa2 gene. Proc. Natl. Acad. Sci. USA 2004, 101:17831-17836.
36. Ison M.G. Adenovirus infections in transplant recipients. Clin. Infect. Dis. 2006, 43:331-339.
37. Kawamata T., Tomari Y. Making RISC. Trends Biochem. Sci. 2010, 35:368-376.
38. Kojaoghlanian T., Flomenberg P., Horwitz M.S. The impact of adenovirus infection on the immunocompromised host. Rev. Med. Virol. 2003, 13:155-171.
39. Koller E., Propp S., Murray H., Lima W., Bhat B., Prakash T.P., Allerson C.R., Swayze E.E., Marcusson E.G., Dean N.M. Competition for RISC binding predicts in vitro potency of siRNA. Nucl. Acids Res. 2006, 34:4467-4476.
40. Lenaerts L., De Clercq E., Naesens L. Clinical features and treatment of adenovirus infections. Rev. Med. Virol. 2008, 18:357-374.
41. Lindemans C.A., Leen A.M., Boelens J.J. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood 2010, 116:5476-5485.
42. Lion T., Baumgartinger R., Watzinger F., Matthes-Martin S., Suda M., Preuner S., Futterknecht B., Lawitschka A., Peters C., Potschger U., Gadner H. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 2003, 102:1114-1120.
43. Lion T., Kosulin K., Landlinger C., Rauch M., Preuner S., Jugovic D., Potschger U., Lawitschka A., Peters C., Fritsch G., Matthes-Martin S. Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation. Leukemia 2010, 24:706-714.
44. Ljungman P., Ribaud P., Eyrich M., Matthes-Martin S., Einsele H., Bleakley M., Machaczka M., Bierings M., Bosi A., Gratecos N., Cordonnier C. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2003, 31:481-486.
45. Lowe S.W., Ruley H.E. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 1993, 7:535-545.
46. Munoz F.M., Piedra P.A., Demmler G.J. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin. Infect. Dis. 1998, 27:1194-1200.
47. Paolino K., Sande J., Perez E., Loechelt B., Jantausch B., Painter W., Anderson M., Tippin T., Lanier E.R., Fry T., DeBiasi R.L. Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001. J. Clin. Virol. 2011, 50:167-170.
48. Pelka P., Ablack J.N., Fonseca G.J., Yousef A.F., Mymryk J.S. Intrinsic structural disorder in adenovirus E1A: a viral molecular hub linking multiple diverse processes. J. Virol. 2008, 82:7252-7263.
49. Rettig, G.R., Behlke, M.A., 2011. Progress toward in vivo use of siRNAs-II. Mol. Ther. (Epub ahead of print). http://dx.doi.org/10.1038/mt.2011.263.
50. Russell W.C. Adenoviruses: update on structure and function. J. Gen. Virol. 2009, 90:1-20.
51. Shaw A.R., Ziff E.B. Transcripts from the adenovirus-2 major late promoter yield a single early family of 3' coterminal mRNAs and five late families. Cell 1980, 22:905-916.
52. Subramanian T., Tarodi B., Chinnadurai G. P53-independent apoptotic and necrotic cell deaths induced by adenovirus infection: suppression by E1B 19K and Bcl-2 proteins. Cell Growth Differ. 1995, 6:131-137.
53. Symeonidis N., Jakubowski A., Pierre-Louis S., Jaffe D., Pamer E., Sepkowitz K., O'Reilly R.J., Papanicolaou G.A. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Transpl. Infect. Dis. 2007, 9:108-113.
54. Tafer H., Ameres S.L., Obernosterer G., Gebeshuber C.A., Schroeder R., Martinez J., Hofacker I.L. The impact of target site accessibility on the design of effective siRNAs. Nat. Biotechnol. 2008, 26:578-583.
55. ter Brake O., Konstantinova P., Ceylan M., Berkhout B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol. Ther. 2006, 14:883-892.
56. Tollefson A.E., Scaria A., Hermiston T.W., Ryerse J.S., Wold L.J., Wold W.S. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 1996, 70:2296-2306.
57. Tribouley C., Lutz P., Staub A., Kedinger C. The product of the adenovirus intermediate gene IVa2 is a transcriptional activator of the major late promoter. J. Virol. 1994, 68:4450-4457.
58. Webster A., Russell S., Talbot P., Russell W.C., Kemp G.D. Characterization of the adenovirus proteinase: substrate specificity. J. Gen. Virol. 1989, 70(Pt. 12):3225-3234.
59. Westerhout E.M., Berkhout B. A systematic analysis of the effect of target RNA structure on RNA interference. Nucl. Acids Res. 2007, 35:4322-4330.
60. White E. Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus. Oncogene 2001, 20:7836-7846.
61. Woo J.L., Berk A.J. Adenovirus ubiquitin-protein ligase stimulates viral late mRNA nuclear export. J. Virol. 2007, 81:575-587.
62. Yusuf U., Hale G.A., Carr J., Gu Z., Benaim E., Woodard P., Kasow K.A., Horwitz E.M., Leung W., Srivastava D.K., Handgretinger R., Hayden R.T. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 2006, 81:1398-1404.
63. Zhang W., Imperiale M.J. Requirement of the adenovirus IVa2 protein for virus assembly. J. Virol. 2003, 77:3586-3594.
64. Zhao H., Granberg F., Elfineh L., Pettersson U., Svensson C. Strategic attack on host cell gene expression during adenovirus infection. J. Virol. 2003, 77:11006-11015.
65. Zhou J., Rossi J.J. Progress in RNAi-based antiviral therapeutics. Methods Mol. Biol. 2011, 721:67-75.